|
Atezolizumab (atezo) with or without Bacille Calmette-Guérin (BCG) in patients (pts) with high-risk nonmuscle-invasive bladder cancer (NMIBC): Results from a phase Ib/II study. |
|
|
Honoraria - Bladder Cancer Academy; PeerView; PlatformQ Health |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Champions Oncology; CicloMed; Ferring; Genentech/Roche; GlaxoSmithKline; Health Advances; Incyte; Janssen; Merck; Mirati Therapeutics; Pfizer/EMD Serono; Principa Biopharma; Seattle Genetics/Astellas; Taris BioMedical; Trans Med |
Research Funding - Acerta Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); HTG Molecular Diagnostics (Inst); Incyte (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Seattle Genetics/Astellas (Inst) |
|
|
Stock and Other Ownership Interests - Epivax Therapeutics; Urogen pharma |
Honoraria - Aduro Biotech; AstraZeneca; Bristol-Myers Squibb; CG Oncology; enGene; Epivax Oncology; fergene; Ferring; Fidia Farmaceutici S. p. A.; FKD Therapies; Janssen Oncology; MDxHealth; Merck; Pfizer; Photocure; Roche/Genentech; Seagen; Sesen Bio; Urogen pharma |
Consulting or Advisory Role - Boston Scientific; CG Oncology; Fidia Farmaceutici S. p. A.; Heat Biologics; MDxHealth; Merck; Natera; photocure; Roche/Genentech; Taris BioMedical |
|
|
Honoraria - Bayer; Dendreon (Inst); Oakstone Publishing; Sun Pharma |
Consulting or Advisory Role - AMRO Pharma (Inst); Bayer (Inst); Bayer (Inst); Clovis Oncology (Inst); Dendreon (Inst); Large Urology Group Practice Association (Inst); Myriad Genetics (Inst); Sanofi (Inst) |
|
Research Funding - Advantage Pharmaceuticals (Inst); Anchiano (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); EMD Serono (Inst); Ferring (Inst); Genentech (Inst); Myovant Sciences (Inst); Myriad Genetics (Inst); Myriad Genetics (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Dendreon; Dendreon (Inst); Myriad Genetics |
|
|
|
Research Funding - Merck Sharp & Dohme Oncology (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - ConMed |
|
|
|
Research Funding - Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Ambu; Ethicon; MSD; Photocure |
|
|
Research Funding - Genentech/Roche |
|
|
|
Consulting or Advisory Role - Photocure |
Research Funding - E.R. Squibb Sons, LLC (Inst); Karl Storz (Inst); MSD (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Covidien; MSD; Photocure |
|
|
|
Consulting or Advisory Role - Janssen |
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Genentech |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech |
Travel, Accommodations, Expenses - Genentech |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Boston Biomedical; Combat Medical; Ferring; Genentech; Nucleix |
Research Funding - Anchiano (Inst); Combat Medical (Inst); Dendreon (Inst); FKD Therapies (Inst); Genentech/Roche (Inst); QED Therapeutics (Inst); Taris BioMedical (Inst); Urogen pharma (Inst) |